Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease

Status:
Terminated

Trial end date:
2010-08-01

Target enrollment:

Participant gender:

This study will assess the safety and efficacy of AIN457 in patients with moderate to severe active Crohn's disease.

Phase 2

Novartis Pharmaceuticals